MCM
DNA icon

MV Capital Management’s Ginkgo Bioworks DNA Stock Holding History

MV Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-137
Closed -$1.12K – 1043
2024
Q3 		$1.12K Sell
137
-1
-0.7% -$10 ﹤0.01% 738
2024
Q2 		$1.84K Sell
138
-1
-0.7% -$30 ﹤0.01% 661
2024
Q1 		$6.43K Buy
139
+1
+0.7% +$52 ﹤0.01% 576
2023
Q4 		$9.29K Hold
138
– – ﹤0.01% 532
2023
Q3 		$9.96K Hold
138
– – ﹤0.01% 500
2023
Q2 		$10.2K Hold
138
– – ﹤0.01% 508
2023
Q1 		$7.32K Hold
138
– – ﹤0.01% 549
2022
Q4 		$9.29K Hold
138
– – ﹤0.01% 469
2022
Q3 		$17K Buy
+138
New +$16.4K ﹤0.01% 355

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

MV Capital Management's DNA Position: Q4 2024 in Review

MV Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 137 shares — an estimated $1.12K sold.

MV Capital Management first reported a position in DNA in Q3 2022 and held it in 9 quarters. The position peaked at $17K in Q3 2022. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • MV Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • MV Capital Management sold 137 Ginkgo Bioworks shares in Q4 2024, an estimated $1.12K.
  • MV Capital Management first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 9 quarters.
  • MV Capital Management's Ginkgo Bioworks position peaked at $17K in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on MV Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.